I only have five minutes, Mr. Warner, so we have to be very brief here. I have lots to get through.
The reason I asked the question is that Mr. DiCarlo is saying that we could be in a scenario in which the virus is mutating and changing. How do we ensure that we have leverage to get vaccines as we go through the next five years? Maybe having one piece of that supply chain is a crucial component. Is there one area we can focus on that allows us to do that?
In the case of the TRIPS waiver, if this thing is changing all the time and if we bring in the TRIPS waiver, what's the incentive for any of the pharmacy companies to actually reinvest in vaccine number three, four, five or vaccine number six?